Molecular analyses of HLA class II-associated susceptibility to subtypes of autoimmune diseases unique to Asians

International Journal of Cardiology

Volumn 66, Issue SUPPL. 1, 1998, Pages

  Nishimura, Yasuharu ^a   Kanai, Takayuki ^a   Oiso, Masatake ^a   Tabata, Hiroki ^a   Ito, Hiroshi ^a   Kira, Jun Ichi ^b   Chen, Yu Zhen ^a   Matsushita, Sho ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Autoimmune disease; Autoreactive T cell; Binding peptide motifs; Disease susceptibility; HLA class II molecule; Self antigenic peptide

Indexed keywords

AUTOANTIGEN; CD4 ANTIGEN; CHOLINERGIC RECEPTOR; DNA; HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; PEPTIDE; T LYMPHOCYTE RECEPTOR;

ALLELE; AUTOIMMUNE DISEASE; BINDING AFFINITY; CONFERENCE PAPER; DISEASE PREDISPOSITION; GENETIC POLYMORPHISM; HLA TYPING; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0032193637     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(98)00156-9     Document Type: Conference Paper

References (79)

1. Germain RN, Margulies DH. The biochemistry and cell biology of antigen processing and presentation. In: WE Paul, Fathman CG, Metzger H, editors. Annual Review of Immunology, Palo Alto, CA: Annual Reviews Inc., 1993;11:403-450.
2. Sette A, Sidney J, Oseroff C, et al. HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions. J Immunol 1993;151:3163-70.
3. Hammer J, Valsasnini P, Tolba K, et al. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 1993;74:197-203.
4. Chicz RM, Urban RG, Gorga JC, Vignali DAA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993;178:27-47.
5. Matsushita S, Takahashi K, Motoki M, Komoriya K, Ikagawa S, Nishimura Y. Allele specificity of structural requirement for peptides bound to HLA-DRB1*0405 and -DRB1*0406 complexes: Implication for the HLA-associated susceptibility to methimazole-induced insulin autoimmune syndrome. J Exp Med 1994;180:873-84.
6. Hammer J, Gallazzi F, Bono E, et al. Peptide binding specificity of HLA-DR4 molecules: Correlation with rheumatoid arthritis association. J Exp Med 1995;181:1847-55.
7. Brown JH, Jardetzky TS, Gorga JC, et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993;364:33-9.
8. Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 1997;7:473-81.
9. Ghosh P, Amaya M, Mellins E, Wiley DC. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995;378:457-62.
10. Stern LJ, Brown JH, Jardetzy TS, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994;368:215-21.
11. Todd JA, Acha-Orbea H, Bell JI, et al. A molecular basis for MHC class II-associated autoimmunity. Science 1988;240:1003-9.
12. Vyse TJ, Todd JA. Reviews on autoimmunity: Genetic analysis of autoimmune disease. Cell 1996;85:311-8.
13. Dong RP, Kimura A, Numano F, Yajima M, Hashimoto Y, Kishi Y, Nishimura Y, Sasazuki T. HLA-DP antigen and Takayasu arteritis. Tissue Antigens 1992;39:106-10.
14. Uchigata Y, Omori Y, Nieda M, Kuwata S, Tokunaga K, Juji T. HLA-DR4 genotype and insulin-processing in insulin autoimmune syndrome. Lancet 1992;340:1467.
15. Nishimura Y, Thorsby E, Rønningen KS, et al. General organization and overview of the disease component. In: Sasazuki T, Aizawa M, Tsuji K, editors. HLA, Oxford: Oxford University Press, 1992;1:693-700.
16. Park MH, Park YB. HLA typing of Takayasu arteritis in Korea. Heart Vess 1992;7:81-4.
17. Mehra NK, Rajalingam R, Sagar S, Jain S, Sharma BK. Direct role of HLA-B5 in influencing susceptibility to Takayasu Aortoarteritis. Int J Cardiol 1996;54(Suppl.):S71-80.
18. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138-46.
19. Kira J-I, Kanai T, Nishimura Y, et al. Western vs. Asian types of multiple sclerosis: Immunogenetically and clinically distinct disorders. Ann Neurol 1996;40:569-74.
20. 57. Hum Immunol 1997;52:47-53.
21. Kanai T, Nomura Y, Segawa M, et al. Immuno-suppressive peptides for a human T cell clone autoreactive to a unique acetylcholine receptor α subunit peptide presented by the disease susceptible HLA-DQ6 in infant-onset myasthenia gravis. Human Immunol 1997;56:28-38.
22. Chen Y-Z, Matsushita S, Nishimura Y. Responses of a human T cell clone to a large panel of altered peptide ligands carrying single residue substitutions in an antigenic peptide: Characterization and frequencies of TCR agonism and TCR antagonism with or without partial activation. J Immunol 1996;157:3783-90.
23. Steinman L. Reviews on autoimmunity, Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system. Cell 1996;85:299-302.
24. Shibasaki H, McDonald WI, Kuroiwa Y. Racial modification of clinical picture of multiple sclerosis: Comparison between British and Japanese patients. J Neurol Sci 1981;49:253-71.
25. Kira J, Tobimatsu S, Goto I, Hasuo K. Primary progressive versus relapsing remitting multiple sclerosis in Japanese patients: A combined clinical, magnetic resonance imaging and multimodality evoked potential study. J Neurol Sci 1993;117:179-85.
26. Olerup O, Hillert J. HLA class II-associated genetic susceptibility in multiple sclerosis: A critical evaluation. Tissue Antigens 1991;38:1-15.
27. Spurkland A, Rønningen KS, Vandvik B, Thorsby E, Vartdal F. HLA-DQA1 and HLA-DQB1 genes may jointly determine susceptibility to develop multiple sclerosis. Hum Immunol 1991;30:69-75.
28. Ota K, Matsui M, Milford EL, Mackin GA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990;346:183-7.
29. Wucherpfennig KW, Sette A, Southwood S, et al. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med 1994;179:279-90.
30. Ødum N, Saida T, Ohta M, Svejgaad A. HLA-DP antigens and HTLV-I antibody studies among Japanese with multiple sclerosis: Evidence for an increased frequency of HLA-DPw4. J Immunogenet 1989;16:467-73.
31. Begovich AB, Helmuth RC, Oksenberg JR, et al. HLA-DPβ and susceptibility to multiple sclerosis: An analysis of Caucasoid and Japanese patient populations. Hum Immunol 1990;28:365-72.
32. Spurkland A, Tabira T, Rønningen KS, Vandvik B, Thorsby E, Vartdal F. HLA-DRB1, -DQA1, -DQB1, -DPA1 and -DPB1 genes in Japanese multiple sclerosis patients. Tissue Antigens 1991;37:171-3.
33. Hao Q, Saida T, Kawakami H, et al. HLAs and genes in Japanese patients with multiple sclerosis: Evidence for increased frequencies of HLA-Cw3, HLA-DR2, and HLA-DQB1*0602. Hum Immunol 1992;35:116-24.
34. Ito H, Yamasaki K, Kawano Y, Horiuchi I, Yun C, Nishimura Y, Kira J. HLA-DP-associated susceptibility to optico-spinal form of multiple sclerosis in the Japanese. Tissue Antigens, 1998;52:179-82.
35. Tisch R, McDevitt H. Reviews on autoimmunity: Insulin-dependent diabetes mellitus. Cell 1996;85:291-7.
36. Todd JA, Bell JI, McDevitt HO. HLA-DQβ gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987;329:599-604.
37. Matsushita S, Nishi T, Yamaoka K, et al. HLA-DQ-binding peptide motifs. I: Comparative binding analysis of type II collagen-derived peptides to DR and DQ molecules of rheumatoid arthritis-susceptible haplotypes. Int Immunol 1996;8:757-64.
38. Kaufman DL, Clare-Salzler M, Tian J, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993;366:69-72.
39. Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, McDevitt HO. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993;366:72-5.
40. Roman MC, Lane WS, Robinson RA, Trucco M, Strominger JL, Gorga JC. Self-peptides bound to the type I diabetes associated class II MHC molecules HLA-DQ1 and HLA-DQ8. Int Immunol 1994;6:1639-49.
41. Sidnem J, Oseroff C, del Guercio MF, et al. Definition of a DQ3.1-specific binding motif. J Immunol 1994;152:4516-25.
42. Kwok WW, Nepom GT, Raymond FC. HLA-DQ polymorphisms are highly selective for peptide binding interactions. J Immunol 1995;155:2468-76.
43. Johansen BH, Vartdal F, Eriksen JA, Thorsby E, Sollid LM. Identification of a putative motif for binding of peptides to HLA-DQ2. Int Immunol 1996;8:177-82.
44. Atkinson MA, Bowman MA, Campbell L, Darrow BL, Kaufman DL, Maclaren NK. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J Clin Invest 1994;94:2125-9.
45. Tian J, Lehmman PV, Kaufman DL. T cell cross-reactivity between coxsackie virus and glutamate decarboxylase is associated with a murine diabetes susceptibility allele. J Exp Med 1994;180:1979-84.
46. Rønningen KS, Spurkland A, Tait BD, et al. HLA class II associations in insulin-dependent diabetes mellitus among Blacks, Caucasoids, and Japanese. In: Sasazuki T, Aizawa M, Tsuji K, editors. HLA, Oxford: Oxford University Press, 1992;1:713-722.
47. Aparicio JM, Wakisaka A, Takada A, Matsuura N, Aizawa M. HLA-DQ system and insulin-dependent diabetes mellitus in Japanese: Does it contribute to the development of IDDM as it does in Caucasians?. Immunogenet 1988;28:240-6.
48. + T cell clones established from Japanese patients with insulin dependent diabetes mellitus. Human Immunol, 1998;59:549-60.
49. De Magistris M, Alexander J, Coggeshall M, et al. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell 1992;68:625-34.
50. Racioppi L, Ronchese F, Matis LA, Germain RN. Peptide-major histocompatibility complexes with mixed agonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signaling. J Exp Med 1993;177:1047-60.
51. Sloan-Lancaster J, Evavold BD, Allen PM. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 1993;363:156-9.
52. Sloan-Lancaster J, Evavold BD, Allen PM. Th2 cell clonal anergy as a consequence of partial activation. J Exp Med 1994;180:1195-205.
53. Evavold BD, Allen PM. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science 1991;252:1308-10.
54. Soloway P, Fish S, Passmore H, Gefter M, Coffte R, Manser T. Regulation of the immune response to peptide antigens: differential induction of immediate-type hypersensitivity and T cell proliferation due to changes in either peptide structure or major histocompatibility complex haplotype. J Exp Med 1991;174:847-58.
55. Windhagen A, Scholz C, Hollsberg P, Fukaura H, Sette A, Hafler DA. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity 1995;2:373-80.
56. Ikagawa S, Matsushita S, Chen YZ, Ishikawa T, Nishimura Y. Single amino acid substitutions on a Japanese cedar pollen allergen (Cry j I)-derived peptide induced alterations in human T cell responses and T cell receptor antagonism. J Allergy Clin Immunol 1996;97:53-64.
57. Matsuoka T, Kohrogi H, Ando M, Nishimura Y, Matsushita S. Altered TCR ligands affect APC responses: Upregulation of IL-12 by an analogue peptide. J Immunol 1996;157:4837-43.
58. Matsushita S, Nishimura Y. Partial activation of human T cells by peptide analogs on live APC: Induction of clonal anergy associated with protein tyrosine dephosphorylation. Human Immunol 1997;53:73-80.
59. Matsushita S, Kohsaka H, Nishimura Y. Evidence for self- and non-self-peptide partial agonists that prolong clonal survival of mature T cells in vitro. J Immunol 1997;158:5685-91.
60. 37 affects recognition of peptides by T cells. Human Immunol 1997;54:30-9.
61. Yokomizo H, Matsushita S, Murakami S, et al. Augmentation of immune response by an analog of the antigenic peptide in a human T-cell clone recognizing mutated Ras-derived peptides. Human Immunol 1997;52:22-32.
62. Engel AG. Myasthenia gravis and myasthenic syndromes. Ann Neurol 1984;16:519-34.
63. Levinson AI, Zweiman B, Lisak RP. Immunopathogenesis and treatment of myasthenia gravis. J Clin Immunol 1987;7:187-97.
64. Christadoss P. Immunogenetics of experimental autoimmune myasthenia gravis. Crit Rev Immunol 1989;9:247-78.
65. Fukuyama Y, Hirayama Y, Osawa M, In: Japan Medical Research Foundation, editors. Myasthenia Gravis. Pathogenesis and Treatment. Tokyo: University of Tokyo Press, 1981.
66. Simpson JA, In: Watson J, editor. Disorders of Voluntary Muscle. London: Churchill Livingstone, 1981.
67. Naeim F, Keesey JC, Herrmann Jr. C, Lindstrom J, Zeller E, Walford RL. Association of HLA-B8, DRw3, and anti-acetylcholine receptor antibodies in myasthenia gravis. Tissue Antigens 1978;12:381-6.
68. Pirskanen R. On the significance of HL-A and LD antigens in myasthenia gravis. Ann NY Acad Sci 1976;274:451-60.
69. Matsuki K, Juji T, Tokunaga K, et al. HLA antigens in Japanese patients with myasthenia gravis. J Clin Invest 1990;86:392-9.
70. Nomura Y, Ehara M, Matsuki K, Juji T, Segawa M. HLA haplotype in myasthenia gravis (MG) of Japanese children. Correlative studies between MG patients and their normal siblings and parents. Ann NY Acad Sci 1993;681:581-3.
71. Raftery MA, Hunkapiller MW, Strader CD, Hood LE. Acetylcholine receptor: Complex of homologous subunits. Science 1980;208:1454-6.
72. Beeson D, Morris A, Vincent A, Newsom-Davis J. The human muscle nicotinic acetylcholine receptor alpha-subunit exists as two isoforms: A novel exon. EMBO J 1990;9:2101-6.
73. Morris A, Beeson D, Jacobson L, Baggi F, Vincent A, Newsom-Davis J. Two isoforms of the muscle acetylcholine receptor alpha-subunit are translated in the human cell line TE671. FEBS Lett 1991;295:116-8.
74. Tzartos SJ, Kokla A, Walgrave SL, Conti-Tronconi BM. Localization of the main immunogenic region of human muscle acetylcholine receptor to residues 67-76 of the alpha subunit. Proc Natl Acad Sci USA 1988;85:2899-903.
75. Moiola L, Protti MP, Manfredi AA, Yuen M-H, Howard Jr. JF, Coti-Tronconi BM. T-helper epitopes on human nicotinic acetylcholine receptor in myasthenia gravis. Ann NY Acad Sci 1993;681:198-218.
76. Willcox N, Baggi F, Batocchi AP, et al. Approaches for studying the pathogenic T cells in autoimmune patients. Ann NY Acad Sci 1993;681:219-37.
77. Manfredi AA, Protti MP, Dalton MW, Howard Jr. JF, Conti-Tronconi BM. T-helper cell recognition of muscle acetylcholine receptor in myasthenia gravis. Epitopes on the gamma and delta subunits. J Clin Invest 1993;92:1055-67.
78. + epitopes. J Immunol 1994;152:4686-98.
79. Matsuo H, Batocchi AP, Hawke S. Peptide-selected T cell lines from myasthenia gravis patient and controls recognize epitopes that are not processed from whole acetylcholine receptor. J Immunol 1995;155:3683-92.